Predictive Oncology (US:POAI) Globenewswireยท2025-08-14 11:00Core Viewpoint - Predictive Oncology reported a loss from continuing operations of approximately $2.0 million for Q2 2025, while focusing on advancing its AI-driven drug discovery and expanding its ChemoFx assay in the U.S. and Europe [1][3]. Financial Summary - The company concluded Q2 2025 with cash and cash equivalents of $506,078, down from $611,822 as of December 31, 2024 [4]. - Revenue for Q2 2025 was $2,682, a significant decrease from $67,255 in Q2 2024, primarily due to reduced sales of tumor-specific 3D models and kits [10]. - General and administrative expenses increased to $1,875,655 in Q2 2025 from $1,825,174 in Q2 2024, mainly due to higher legal fees [10]. - The company raised approximately $586,000 in gross proceeds during the quarter through private placements and its At-the-Market facility [6]. Operational Highlights - The company is preparing for an aggressive market expansion of its ChemoFx assay in the U.S. and a de novo launch in Europe, both expected in Q4 2025 [5]. - ChemoFx helps oncologists make better treatment decisions by testing multiple chemotherapies on patients' cancer cells before treatment selection [5]. - Predictive Oncology has developed two unique 3D liver toxicity models for Labcorp, which can evaluate drug metabolism and liver toxicity [5]. - The company identified three promising candidates for repurposing from abandoned drugs, specifically Afuresertib, Alisertib, and Entinosta, for colon and breast tumor indications [5]. Capital and Investment - A standby equity purchase agreement for up to $10 million was announced with YA II PN, LTD, managed by Yorkville Advisors Global, LP, providing a flexible source of capital for advancing initiatives [5].